Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
In Czechia, labelled drug-related public expenditure is regularly monitored. The current drug strategy calls for the budgeting of planned drug-related initiatives, and the associated action plan identifies, for each activity, a planned time frame, specifying institution(s), output indicators and funding requirements. Between 2007 and 2010, unlabelled expenditures and indirect social costs were also estimated using a ‘cost of illness’ methodology.
In 2017, the total identified drug-related public expenditure amounted to EUR 66.7 million, representing 0.03 % of gross domestic product (GDP), or double the estimate from a decade ago. Of this, 59 % funded supply reduction activities, 41 % funded demand reduction (with treatment and harm reduction receiving the largest proportion of this expenditure) and 3 % was allocated to transversal initiatives, such as coordination, research and evaluation. Long-term trend analysis indicates that total expenditure has increased gradually since 2013 in nominal terms, while it has remained stable as a proportion of GDP.